Zimmer Biomet Holdings Inc 报告称，2023 年第四季度和全年净销售额为 19.4 亿美元/73.94 亿美元，归功于需求和重组，预计 4。 Zimmer Biomet Holdings Inc reported Q4 and full-year 2023 net sales of $1.940bn/$7.394bn, crediting demand and restructuring, projecting 4.

医疗技术公司 Zimmer Biomet Holdings Inc 在 2023 年第四季度和全年业绩中表现强劲，该季度和全年净销售额分别达到 19.4 亿美元和 73.94 亿美元。 Zimmer Biomet Holdings Inc, a medical technology company, reported a solid performance in its Q4 and full-year 2023 results, with net sales reaching $1.940 billion and $7.394 billion for the quarter and the full year, respectively. 该公司将其成功归因于对其医疗设备的持续需求以及 2021 年底启动的重组计划。Zimmer Biomet 预计来年报告收入变化为 4.5% 至 5.5%，调整后摊薄每股收益为 8.00 美元至 8.15 美元。 The company attributed its success to persistent demand for its medical devices and a restructuring program initiated in late 2021. Zimmer Biomet projected a reported revenue change of 4.5% to 5.5% and an adjusted diluted EPS of $8.00 to $8.15 for the upcoming year.